Repressor

Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Monday, August 7, 2023
PK, SDMA, MTAP, CRISPR, Senior, Jannik, GBM, Repressor, MTA, Senior advisor, Clinical trial, Pharmacokinetics, Mutation, Traffic barrier, Histology, Breast, Research, NSCLC, STK11, Carcinoma, Glioblastoma, RCOR1, Animal, Jannik Madum Andersen, Patient, Drug discovery, Cancer, Neoplasm, FDA, Pembrolizumab, Collaboration, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Therapy, Food, Safety, PRMT5, Pharmaceutical industry, Vaccine, Medical imaging, Management, Arms industry, Biology

BOSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the second quarter ended June 30, 2023, and provided business highlights.

Key Points: 
  • “We have significantly advanced our pipeline since the first quarter, including bringing two novel agents into phase 1/2 clinical trials.
  • Alan plans to start a new company outside of our focus, which will incubate in Tango labs, facilitating his advisor role to Tango.
  • Alan played a pivotal role founding Tango and has been an integral part of the Company from inception.
  • The increase is the result of out-licensing a program to Gilead for $5.0 million during the second quarter of 2023.

Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers

Retrieved on: 
Monday, July 24, 2023
PK, Repressor, Clinical trial, Pharmacokinetics, Mutation, Breast, Fast Track, Lung cancer, Immunotherapy, STK11, Carcinoma, Development, RCOR1, Animal, Patient, Cancer, Neoplasm, Pembrolizumab, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry, Research

BOSTON, July 24, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trial evaluating TNG260 in combination with pembrolizumab in patients with STK11-mutant cancers.

Key Points: 
  • BOSTON, July 24, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trial evaluating TNG260 in combination with pembrolizumab in patients with STK11-mutant cancers.
  • TNG260 is a first-in-class inhibitor of the CoREST complex (Co-repressor of Repressor Element-1 Silencing Transcription).
  • “The TNG260 phase 1/2 clinical trial is the first trial to use genetic patient selection in combination with checkpoint inhibitor therapy to reverse the cancer-specific immune evasion caused by STK11 loss of function mutations.
  • Resistance to immunotherapy is a major challenge faced by patients with STK11-mutant cancers, which TNG260 is specifically designed to overcome,” said Adam Crystal, M.D., Ph.D., President of Research and Development of Tango Therapeutics.

Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Tuesday, May 9, 2023
PK, SDMA, MTAP, AACR, GBM, Repressor, MTA, Bone marrow suppression, Therapeutic index, Clinical trial, Pharmacokinetics, Mutation, Traffic barrier, Histology, Fast Track, Breast, NSCLC, STK11, Carcinoma, Tango, Glioblastoma, PRMT5, Research and development, RCOR1, American Association for Cancer Research, Patient, Cancer, Annual general meeting, Neoplasm, Infrared spectroscopy correlation table, FDA, Pembrolizumab, Collaboration, Therapy, IND, FTD, Safety, Pharmaceutical industry, Vaccine, Research

BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2023, and provided business highlights.

Key Points: 
  • We look forward to providing additional data from the trial in 2024,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics.
  • TNG908 proof-of-mechanism as an MTA-cooperative PRMT5 inhibitor demonstrated by marked SDMA reduction in MTAP-deleted cancer cells versus normal tissue.
  • The TNG462 Investigational New Drug (IND) application cleared in January 2023, and the first patient is expected to be dosed in mid-2023.
  • General and administrative expenses were $8.0 million for the three months ended March 31, 2023, compared to $6.8 million for the same period in 2022.

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant Cancers

Retrieved on: 
Monday, April 3, 2023
Repressor, Pharmacokinetics, Mutation, Breast, NSCLC, Lung cancer, STK11, Carcinoma, RCOR1, Patient, Immune system, Cancer, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Pharmaceutical industry

“FDA clearance of our IND application to initiate the TNG260 phase 1/2 trial is an important milestone in the development of this novel treatment for STK11-mutant cancers.

Key Points: 
  • “FDA clearance of our IND application to initiate the TNG260 phase 1/2 trial is an important milestone in the development of this novel treatment for STK11-mutant cancers.
  • STK11 mutations drive resistance to standard of care immunotherapy and are a major challenge in treating many cancers, including non-small cell lung cancer,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics.
  • “We expect that TNG260 will be among the first oncology molecules to leverage the benefits of genetically-based patient selection (STK11-mutation) with checkpoint inhibitor therapy.
  • The CoREST complex has been shown to play a major role in regulating the expression of immunomodulatory proteins in STK11-mutant cancers.

Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights

Retrieved on: 
Monday, March 27, 2023
Abstract, MTAP, AACR, GBM, Repressor, MTA, ODD, Therapeutic index, Clinical trial, Ovary, Mutation, Traffic barrier, Breast, Prostate, Lung cancer, STK11, Carcinoma, Glioblastoma, USP1, PRMT5, Non-small-cell lung cancer, Research and development, Development, RCOR1, Investigational New Drug, American Association for Cancer Research, Patient, Immune system, Cancer, Annual general meeting, Mesothelioma, Drug discovery, BRCA, FDA, Collaboration, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, FTD, PARP, Food, Glioma, Cholangiocarcinoma, Pharmaceutical industry, Vaccine, Birth control, Cryptocurrency, BRCA1, Research

BOSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2022, and provided business highlights.

Key Points: 
  • “2022 was an important year for Tango, as we made critical strides in advancing our programs.
  • In the fourth quarter of 2022, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to TNG908 for the treatment of malignant glioma (GBM).
  • TNG908 is an MTA-cooperative inhibitor of PRMT5 that works selectively in cancer cells with MTAP deletion.
  • MTAP deletions occur in approximately 10%-15% of all human cancers, including non-small cell lung cancer, mesothelioma, cholangiocarcinoma and GBM.

Tango Therapeutics Announces Presentation of Preclinical Data on TNG260 and Discovery Platform Advances at SITC 37th Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
Time, Pancreatic cancer, Sale, STK11, SEC, Therapy, RCOR1, IND, SITC, Annual report, NASDAQ, Neoplasm, Patient, Investigational New Drug, Program, Repressor, Annual general meeting, Immunotherapy, Risk, Precision medicine, Cancer, Technology, Escape Room, Goal, Company, Society, Breast cancer, Cervical cancer, Patent, Safety, 2021 Essex County Council election, Carcinoma, Survival, GLOBE, Clinical trial, Intellectual property, Forward-looking statement, Terminology, COVID-19, Society for Immunotherapy of Cancer, Human, Large-cell lung carcinoma, Pharmaceutical industry, Vaccine, IND World's Fair Line

We are looking forward to presenting data on TNG260, a novel, highly selective CoREST inhibitor with the potential to reverse the immune evasion driven by STK11 loss-of-function mutations.

Key Points: 
  • We are looking forward to presenting data on TNG260, a novel, highly selective CoREST inhibitor with the potential to reverse the immune evasion driven by STK11 loss-of-function mutations.
  • TNG260 is a novel small molecule inhibitor of the Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) deacetylase complex.
  • TNG260 is being developed to reverse immune evasion in STK11 mutated cancers, with the aim of restoring sensitivity to immune checkpoint inhibition.
  • The Company expects to file an Investigational New Drug (IND) application for TNG260 in the first half of 2023.